U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H36N4O2S
Molecular Weight 492.676
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LURASIDONE

SMILES

O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)C6=NSC7=C6C=CC=C7

InChI

InChIKey=PQXKDMSYBGKCJA-CVTJIBDQSA-N
InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula C28H36N4O2S
Molecular Weight 492.676
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK and is also approved in the USA and Canada for the treatment of bipolar depression as either a monotherapy or adjunctive therapy with lithium or valproate. In addition, lurasidone is in phase III of a clinical trial for the treatment patient with major depressive disorder and for the treatment of irritability associated with autistic disorder. The mechanism of action of lurasidone, as with other drugs having efficacy in schizophrenia, is unknown but is known, that lurasidone has a high affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, lurasidone is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine or muscarinic receptors.

Approval Year

PubMed

PubMed

TitleDatePubMed
Iloperidone, asenapine and lurasidone: a primer on their current status.
2012 Sep
Newer antipsychotics and upcoming molecules for schizophrenia.
2013 Aug
Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.
2013 Jan
Patents

Patents

Sample Use Guides

In Vivo Use Guide
The recommended starting dose of LATUDA ((LURASIDONE HCL) is 40 mg once daily. LATUDA has been shown to be effective in a dose range of 40 mg/day to 120 mg/day. In the 6-week controlled trials, there was no suggestion of added benefit with the 120 mg/day dose, but there was a dose -related increase in certain adverse reactions. Therefore, the maximum recommended dose is 80 mg/day
Route of Administration: Oral
In Vitro Use Guide
[35S]GTPγS binding experiments for the human dopamine D2L or 5-HT1A receptors stably expressed in the membranes of recombinant Chinese hamster ovary (CHO) cells were performed. After dopamine (or serotonin) and/or lurasidone were incubated for 20 min at room temperature with the cell membrane preparation containing [35S]GTPγS (0.05 nM for D2L or 0.2 nM for 5-HT1A), the membranes were filtered through glass filters and the radioactivity bound to each filter was measured with a liquid scintillation counter. For nonspecific binding, cold GTPγS (20 μM for D2L or 10 μM for 5-HT1A) was added with [35S]GTPγS. in vitro receptor binding experiments revealed that lurasidone demonstrates affinity for dopamine D2 and 5-HT2A receptors higher than other tested antipsychotics. In contrast to other agents, lurasidone also displayed high affinity for 5-HT7, 5-HT1A, and noradrenaline α2C receptors.
Substance Class Chemical
Created
by admin
on Mon Oct 21 23:55:07 UTC 2019
Edited
by admin
on Mon Oct 21 23:55:07 UTC 2019
Record UNII
22IC88528T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LURASIDONE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
LURASIDONE [VANDF]
Common Name English
LURASIDONE [MI]
Common Name English
LATUDA
Brand Name English
LURASIDONE [WHO-DD]
Common Name English
LURASIDONE [INN]
Common Name English
Classification Tree Code System Code
LIVERTOX 578
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
NCI_THESAURUS C66885
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
WHO-ATC N05AE05
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
WHO-VATC QN05AE05
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
EMA ASSESSMENT REPORTS LATUDA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
NDF-RT N0000175430
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
NCI_THESAURUS C66883
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
Code System Code Type Description
RXCUI
1040028
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY RxNorm
ChEMBL
CHEMBL1237021
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
PUBCHEM
213046
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
IUPHAR
7461
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
EVMPD
SUB32185
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
NCI_THESAURUS
C77575
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
WIKIPEDIA
Lurasidone
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
DRUG BANK
DB08815
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
CAS
367514-87-2
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
INN
8247
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
MESH
C525644
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
LactMed
367514-87-2
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
MERCK INDEX
M6943
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY Merck Index
HSDB
367514-87-2
Created by admin on Mon Oct 21 23:55:07 UTC 2019 , Edited by admin on Mon Oct 21 23:55:07 UTC 2019
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
MODERATE
METABOLIC ENZYME -> INHIBITOR
MODERATE
EXCRETED UNCHANGED
Total excretion of the dose recovered in urine and feces combined was 89.3%, with 80.1% recovered in feces and 9.2% in urine
FECAL; URINE
METABOLIC ENZYME -> INHIBITOR
MODERATE
METABOLIC ENZYME -> INHIBITOR
MODERATE
TARGET -> AGONIST
SHORT-ACTING
BINDER->LIGAND
BINDING
TRANSPORTER -> NON-SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
MODERATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC single dose administration

Biological Half-life PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC single dose administration

Tmax PHARMACOKINETIC multiple dose administration

Volume of Distribution PHARMACOKINETIC single dose administration